Plerixafor
- CAS No.
- 1246819-87-3
- Chemical Name:
- Plerixafor
- Synonyms
- Plerixafor-d4;[2H4]-Plerixafor;Paclobutrazol Impurity 6
- CBNumber:
- CB82545583
- Molecular Formula:
- C28H54N8
- Molecular Weight:
- 502.78196
- MDL Number:
- MFCD19705148
- MOL File:
- 1246819-87-3.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Plerixafor-d4 ≥99%deuteratedforms(d1-d4) | 26490 | 1mg | $253 |
| Plerixafor-d4 | 26490 | 500μg | $121 |
| Plerixafor-d4 | 26490 | 1mg | $230 |
| Plerixafor-d4 | TRC-P580502-1MG | 1mg | $215 |
| Plerixafor-d4 | TRC-P580502-10MG | 10mg | $1686 |
| More product size | |||
Plerixafor price More Price(21)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 26490 | Plerixafor-d4 ≥99%deuteratedforms(d1-d4) | 1246819-87-3 | 1mg | $253 | 2026-04-30 | Buy |
| Cayman Chemical | 26490 | Plerixafor-d4 | 1246819-87-3 | 500μg | $121 | 2024-03-01 | Buy |
| Cayman Chemical | 26490 | Plerixafor-d4 | 1246819-87-3 | 1mg | $230 | 2024-03-01 | Buy |
| TRC | TRC-P580502-1MG | Plerixafor-d4 | 1246819-87-3 | 1mg | $215 | 2026-06-03 | Buy |
| TRC | TRC-P580502-10MG | Plerixafor-d4 | 1246819-87-3 | 10mg | $1686 | 2026-06-03 | Buy |
Plerixafor Chemical Properties,Uses,Production
Description
Plerixafor-d4 is intended for use as an internal standard for the quantification of plerixafor by GC- or LC-MS. Plerixafor is a partial antagonist of chemokine receptor 4 (CXCR4) with IC50 values ranging from 0.02 to 0.13 μg/ml for inhibiting calcium flux in peripheral blood mononuclear cells (PBMCs), various types of T cells, and mouse lymphocytic leukemia cells. It is selective for CXCR4 over CXCR1-3 and CXCR5-9 (IC50s = >25 μg/ml). Plerixafor decreases infectious virus content in the supernatant of Jurkat cells chronically infected with HIV-1(IIIB) (EC50 = ~0.02 μg/ml). It rapidly mobilizes murine and human hematopoietic stem and murine long-term repopulating cells for transplantation alone and, with a synergistic effect, when used in combination with G-CSF. Plerixafor also increases T cell trafficking in mouse blood, spleen, and central nervous system. Plerixafor (1.25 mg/kg twice per day) decreases the number of 4T1 murine mammary carcinoma cells in the lung in a mouse model of lung metastasis.
Chemical Properties
Off-White Solid
Uses
Labelled Plerixafor, it is a hematopoietic stem cell (HSC) mobilizer that inhibits the CXCR4 chemokine receptor and blocks binding of its ligand, stromal cell-derived factor-1-α (SDF-1-α). This agent was approved on Dec. 15, 2008, as treatment in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize HSCs to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin''s lymphoma (NHL) and multiple myeloma (MM).
References
[1] SIGRID HATSE. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4[J]. FEBS Letters, 2002, 527 1-3: 255-262. DOI: 10.1016/s0014-5793(02)03143-5
[2] E DE CLERCQ. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.[J]. Antimicrobial Agents and Chemotherapy, 1994, 38 4: 668-674. DOI: 10.1128/aac.38.4.668
[3] DAVID A. HESS . Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized by Granulocyte Colony Stimulating Factor[J]. Biology of Blood and Marrow Transplantation, 2007, 13 4: Pages 398-411. DOI: 10.1016/j.bbmt.2006.12.445
[4] GIOVANNI BERNARDINI. CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets.[J]. Blood, 2008, 111 7: 3626-3634. DOI: 10.1182/blood-2007-08-106203
[5] ERIN E MCCANDLESS. CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105 32: 11270-11275. DOI: 10.1073/pnas.0800898105
[6] MATTHEW C P SMITH. CXCR4 regulates growth of both primary and metastatic breast cancer.[J]. Cancer research, 2004, 64 23: 8604-8612. DOI: 10.1158/0008-5472.can-04-1844
Plerixafor Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Alfa Chemistry | +1-5166625404; | Info@alfa-chemistry.com | United States | 20405 | 58 |
| J & K SCIENTIFIC LTD. | 18210857532; 18210857532 | jkinfo@jkchemical.com | China | 96815 | 76 |
| Chemsky（shanghai）International Co.,Ltd. | 021-50135380 | shchemsky@sina.com | China | 32321 | 50 |
| Hubei Yangxin Medical Technology Co., Ltd. | 15374522761 | 3003392093@yongstandards.com | China | 9929 | 55 |
| Shenzhen Polymeri Biochemical Technology Co., Ltd. | +86-400-002-6226 +86-13028896684; | sales@rrkchem.com | China | 57422 | 58 |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 | sales@chemegen.com | China | 11218 | 58 |
| Energy Chemical | 021-58432009 400-005-6266 | marketing1@energy-chemical.com | China | 44896 | 58 |
| Shanghai Universal Biotech Co.,Ltd | 15921930842 15921930842 | yh-wang@univ-bio.com | China | 25022 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11972 | 58 |
| Nanjing Shizhou Biology Technology Co.,Ltd | 17301488900 | judy.xia@synzest.com | China | 12582 | 58 |
